Biotechnology Fund Fcpr Net Worth

The estimated Net Worth of Biotechnology Fund Fcpr is at least $413 Mille dollars as of 7 May 2014. Biotechnology Fcpr owns over 50,000 units of Scynexis Inc stock worth over $413,108 and over the last 10 years Biotechnology sold SCYX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Biotechnology Fcpr SCYX stock SEC Form 4 insiders trading

Biotechnology has made over 1 trades of the Scynexis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Biotechnology bought 50,000 units of SCYX stock worth $500,000 on 7 May 2014.

The largest trade Biotechnology's ever made was buying 50,000 units of Scynexis Inc stock on 7 May 2014 worth over $500,000. On average, Biotechnology trades about 50,000 units every 0 days since 2014. As of 7 May 2014 Biotechnology still owns at least 295,077 units of Scynexis Inc stock.

You can see the complete history of Biotechnology Fcpr stock trades at the bottom of the page.

What's Biotechnology Fcpr's mailing address?

Biotechnology's mailing address filed with the SEC is 57 RUE DE RICHELIEU, , PARIS, I0, 75002.

Insiders trading at Scynexis Inc

Over the last 10 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado e Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.

What does Scynexis Inc do?

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Complete history of Biotechnology Fcpr stock trades at Scynexis Inc

Scynexis Inc executives and stock owners

Scynexis Inc executives and other stock owners filed with the SEC include:

• Dr. Marco Taglietti M.D.,
  CEO, Pres & Director
• Dr. Marco Taglietti,
  CEO, Pres & Director
• David Gonzalez Angulo,
  Chief Medical Officer
• Eric Francois,
  Chief Financial Officer
• Christine R. Coyne M.B.A.,
  Chief Commercial Officer
• Philippe Tinmouth,
  Director
• Jean-Yves Nothias,
  Director
• Guy Macdonald,
  Director
• Patrick Langlois,
  Director
• David Hastings,
  Director
• Ann Hanham,
  Director
• Steven Gilman,
  Director
• Laurent Arthaud,
  Director
• Armando Anido,
  Director
• David Angulo,
  Chief Medical Officer
• Scott Sukenick,
  General Counsel
• Nkechi Azie,
  Vice President - Clinical Development
• Jim Maffezzoli,
  Vice President of Sales and Marketing
• Eric Francois,
  Chief Financial Officer
• Marco Taglietti,
  President, Chief Executive Officer, Director
• Pamela Kirby,
  Chairman of the Board
• Debbie Etchison,
  Exec. Director of Communications
• Lawrence R. Hoffman CPA, Esq.,
  Interim CFO & Principal Accounting Officer
• Dr. Rajeshwar Motheram,
  Sr. VP of Pharmaceutical Devel. & Supply Chain
• Scott Sukenick J.D.,
  Gen. Counsel & Corp. Sec.
• Patrick Machado,
  Director
• Marion Mc Court,
  Director
• Jr. Charles F Osborne,,
  Chief Financial Officer
• Biopharma Partners Ii Lpalt...,
  
• Carole Sable,
  Chief Medical Officer
• Capital Ii Ventech,
  10% owner
• Biotechnology Fund Fcpr,
  10% owner
• Eileen Pruette,
  General Counsel
• Genavent F.C.P.R.,
  10% owner
• Mounia Chaoui,
  Director
• Edward Penhoet,
  Director
• Yves J Ribeill,
  President and CEO
• Advisors Llcperceptive Life...,
  
• Christine Coyne,
  Chief Commercial Officer
• Ivor Macleod,
  Chief Financial Officer